

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:esapal653adk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 28 PATDPFULL - New display fields provide for legal status  
data from INPADOC  
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available  
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN  
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced  
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 8 MAR 22 KORSAPAT now updated monthly; patent information enhanced  
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY  
NEWS 10 MAR 22 PATDPASPC - New patent database available  
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags  
NEWS 12 APR 04 BPFULL enhanced with additional patent information and new  
fields  
NEWS 13 APR 04 EMBASE - Database reloaded and enhanced  
NEWS 14 APR 18 New CAS Information Use Policies available online  
NEWS 15 APR 25 Patent searching, including current-awareness alerts (SDIs),  
based on application date in CA/CAPLUS and USPATFULL/USPAT2  
may be affected by a change in filing date for U.S.  
applications.  
NEWS 16 APR 28 Improved searching of U.S. Patent Classifications for  
U.S. patent records in CA/CAPLUS  
NEWS 17 MAY 23 GBFULL enhanced with patent drawing images  
NEWS 18 MAY 23 REGISTRY has been enhanced with source information from  
CHEMCATS  
NEWS 19 JUN 06 STN Patent Forums to be held in June 2005  
NEWS 20 JUN 06 The Analysis Edition of STN Express with Discover!  
(Version 8.0 for Windows) now available  
NEWS 21 JUN 13 RUSSAPAT: New full-text patent database on STN  
NEWS 22 JUN 13 FRFULL enhanced with patent drawing images  
NEWS 23 JUN 20 MEDICINF to be removed from STN  
NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0c(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 07:28:10 ON 24 JUN 2005

| Cost in U.S. Dollars | Since File Entry | Total Session |
|----------------------|------------------|---------------|
|                      | 0.21             | 0.21          |

FILE 'REGISTRY' ENTERED AT 07:28:19 ON 24 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2005 HIGHEST RN 852898-09-0  
DICTIONARY FILE UPDATES: 23 JUN 2005 HIGHEST RN 852898-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*



Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
information enter HELP PROP at an arrow prompt in the file or refer  
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registries.html>

==>

Uploading H:\STN queries\098794421.str



Structure attributes must be viewed using STN Express query preparation.

chain nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25 26 27 28 29 30 31 32  
chain bonds :  
1-3 1-2 3-4 3-29 4-5 5-6 5-7 6-8 6-17 9-14 9-10 9-18 10-11 11-12 11-  
13 14-15 15-16 15-20 17-18 18-19 20-21 21-22 22-23 23-24 23-25 25-26  
26-28 26-27 29-30 30-31 30-32  
exact/norm bonds :  
1-2 3-4 4-5 5-7 6-17 9-14 14-15 15-16 17-18 18-19 21-22 22-23 23-24  
23-25 25-26 26-28 26-27  
exact bonds :  
1-3 3-29 5-6 6-8 9-10 9-18 10-11 11-12 11-13 15-20 20-21 29-30 30-31  
30-32  
Match level :  
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS  
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS  
26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS

L1 STRUCTURE UPLOADED

==> die l1

L1 HAS NO ANSWERS

L1 STR

==> e l1 ful

FULL SEARCH INITIATED 07:28:40 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 168398 TO ITERATE

100.0% PROCESSED 168398 ITERATIONS  
SEARCH TIME: 00.00.14

21 ANSWERS

L2 21 SEA SSS FUL L1

==> e doxorubicin

|     |         |                     |
|-----|---------|---------------------|
| E1  | 109     | DOXORUBI/BI         |
| E2  | 2       | DOXORUBI/BI         |
| E3  | 109 --> | DOXORUBI/BI         |
| E4  | 6       | DOXORUBICINOL/BI    |
| E5  | 2       | DOXORUBICINOLONE/BI |
| E6  | 2       | DOXORUBICINON/BI    |
| E7  | 2       | DOXORUBICINONE/BI   |
| E8  | 2       | DOXPICOD/BI         |
| E9  | 2       | DOXPICODI/BI        |
| E10 | 2       | DOXPICODIN/BI       |
| E11 | 2       | DOXPICOMINS/BI      |
| E12 | 1       | DOXS/BI             |

==> e e3

L3 109 DOXORUBICIN/BI

==> l3 and l2

L4 0 L3 AND L2


==> fil hcaplus

| Cost in U.S. Dollars | Since File Entry | Total Session |
|----------------------|------------------|---------------|
|                      | 166.36           | 166.57        |

FILE 'HCAPLUS' ENTERED AT 07:29:39 ON 24 JUN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

### Absolute stereochemistry.

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.  
The MAX format is the same as ALL.  
The IALL format is the same as ALL with BIB ABS and IND indented.



L5 ANSWER 2 OF 13 HCAPLIP COPYRIGHT 2005 ACS ON STW  
 ACCESSION NUMBER: 2004:857758 HCAPLIP Full-Text  
 DOCUMENT NUMBER: 141:325667  
 TITLE: Allosteric nucleic acid probes and their use in  
 disease diagnosis and treatment  
 INVENTOR(S): Nilsen-Hamilton, Marit  
 PATENT ASSIGNER(S): Iowa State University Research Foundation, Inc., USA  
 SOURCE: PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO. | KIND        |     | DATE |     | APPLICATION NO. |     | DATE        |     |
|------------|-------------|-----|------|-----|-----------------|-----|-------------|-----|
| CO         | 20040088279 |     | A2   |     | 20040101014     |     | 20040326036 |     |
| W:         | AS,         | AG, | AL,  | AM, | AT,             | AU, | AZ,         | BA, |
|            | BB,         | BD, | BG,  | BR, | BS,             | BY, | BZ,         | CA, |
|            | CC,         | CD, | CF,  | CG, | CH,             | CN, | CZ,         | DE, |
|            | DK,         | DM, | DO,  | DR, | DU,             | EE, | EG,         | ES, |
|            | GB,         | GH, | GM,  | HN, | HU,             | ID, | IL,         | IN, |
|            | IS,         | IT, | JP,  | KE, | KG,             | KP, | KR,         | KZ, |
|            | LA,         | LR, | LS,  | LT, | LV,             | LY, | MA,         | MC, |
|            | MD,         | MG, | MK,  | ML, | MM,             | MO, | MN,         | MR, |
|            | MT,         | MU, | NZ,  | OM, | PG,             | PH, | PL,         | PT, |
|            | RO,         | RU, | SC,  | SD, | SE,             | SG, | SI,         | SK, |
|            | TM,         | TH, | TN,  | TR, | TT,             | UA, | UG,         | UY, |
|            | VE,         | VN, | ZA,  | ZM, | ZW,             |     |             |     |
| RW:        | BW,         | CH, | CM,  | CG, | CI,             | DK, | DM,         | DO, |
|            | DR,         | DU, | EE,  | EG, | ES,             | GB, | GH,         | GM, |
|            | HN,         | HU, | ID,  | IL, | IN,             | IS, | JP,         | KE, |
|            | KG,         | KP, | KR,  | KZ, | LA,             | LR, | LS,         | LT, |
|            | LV,         | LY, | MA,  | MC, | MD,             | MG, | ML,         | MM, |
|            | MO,         | MN, | MR,  | MT, | MU,             | NZ, | OM,         | PG, |
|            | PH,         | PL, | PT,  | RO, | RU,             | SC, | SD,         | SE, |
|            | SG,         | SI, | SK,  | SL, | SM,             | SN, | SR,         | SS, |
|            | ST,         | SV, | TD,  | TE, | TF,             | TH, | TI,         | TJ, |
|            | TM,         | TN, | TR,  | TT, | UA,             | UG, | UY,         | UZ, |
|            | VE,         | VN, | ZA,  | ZM, | ZW,             |     |             |     |


BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005026178 A1 20050203 US 2004-809886 20040326  
PRIORITY APPLN. INFO.: US 2003-457936P P 20030328


IT 274912-87-7, CPI-0004Na  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (allosteric regulator or target; allosteric nucleic acid probes and their use in disease diagnosis and treatment)

RN 274912-87-7 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




LS ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:780503 HCAPLUS Full-text  
DOCUMENT NUMBER: 141:289012  
TITLE: Paclitaxel hybrid derivatives with improved properties for the treatment of cancer  
INVENTOR(S): Erhardt, Paul W.; Klia, Weislaw A.; Sarver, Jeffrey G.  
PATENT ASSIGNEE(S): The University of Toledo, USA  
SOURCE: PCT Int. Appl., 43 pp.


LANGUAGE: English  
IT 274912-87-7, CPI 0004Na  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (doxorubicin prodrug CPI-0004Na significantly reduced 3LL-H61 carcinoma cell lung metastases in mouse than doxorubicin suggesting its potent anti-tumor activity)

RN 274912-87-7 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:733803 HCAPLUS Full-text  
DOCUMENT NUMBER: 140:156884  
TITLE: CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors  
AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.; Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.;

CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2004080412 | A2   | 20040923 | WO 2004-US7269  | 20040305 |
| WO 2004080412 | A3   | 20050526 |                 |          |


W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GR, GE, GH, GM, GN, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-452649P P 20030307  
OTHER SOURCE(S): MARPAT 141:289012  
IT 274912-04-1D, conjugates with paclitaxel  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (paclitaxel derivs. with improved properties for treatment of cancer)

RN 274912-04-1 HCAPLUS  
CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




LS ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:765541 HCAPLUS Full-text  
DOCUMENT NUMBER: 142:106748  
TITLE: CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57B1/6 mice  
AUTHOR(S): Dasnoles, Luc; Lebtschi, Karim; Abarca-Quinones, Jorge; Havaux, Nathalie; Dupont, Samuel; Dubois, Vincent; Trouet, Andie  
CORPORATE SOURCE: Laboratory of Cell Biology & Institut des Sciences de la Vie, Université catholique de Louvain, Louvain-La-Neuve, B-1348, Belg.  
SOURCE: Journal of Experimental Therapeutics and Oncology (2004), 4(2), 167-169  
CODEN: JETOPX; ISSN: 1359-4117  
PUBLISHER: Old City Publishing  
DOCUMENT TYPE: Journal


Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; Zhou, Fengmin; Salles, Adam; Chen, Teeng-Hui; Horgen, Killian; Wang, Yi-Hong; Nguyen, Thi; Bebbington, Christopher R.  
Corixa Corp., South San Francisco, CA, 94080, USA  
Cancer Research (2003), 63(17), 5526-5531  
CODEN: CNREAS; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 274912-87-7, CPI 0004Na  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (metalloprotease CD10 role in activation of tumor-activated peptide prodrug CPI-0004Na and novel analogs)

RN 274912-87-7 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:964147 HCAPLUS Full-text  
DOCUMENT NUMBER: 138:29142  
TITLE: CD10-activated prodrug compounds  
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin  
PATENT ASSIGNER(S): Medarex, Inc., USA  
SOURCE: PCT Int. Appl., 167 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| WO 2002100353   | A2   | 20021219 | WO 2002-US21135 | 20020610 |
| WO 2002100353   | A3   | 20030522 |                 |          |
| W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2450316  | AA   | 20021219 | CA 2002-2450316 | 20020611 |
| EP 1404356  | A2   | 20040407 | EP 2002-746852  | 20020611 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |      |          |                 |          |
| US 2004087497   | A1   | 20040506 | US 2002-167627  | 20020611 |
| US 6897034  | B2   | 20050524 |                 |          |
| JP 2004537527   | T2   | 20041216 | JP 2003-503179  | 20020611 |
| PRIORITY APPLN. INFO.: US 2001-297596P P 20010611   |      |          |                 |          |
| WO 2002-US21135 W 20020611  |      |          |                 |          |

OTHER SOURCE(S): MARPAT 138:29142

IT 274912-87-7P


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(oligopeptide-containing prodrugs activated by CD10 antigen)  
RN 274912-87-7 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B




IT 274912-96-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(oligopeptide-containing prodrugs activated by CD10 antigen)  
RN 274912-96-8 HCAPLUS  
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 274913-07-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(oligopeptide-containing prodrugs activated by CD10 antigen)  
RN 274913-07-4 HCAPLUS  
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxohexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2448319 AA 20021205 CA 2002-2448319 20020531  
US 2003050331 A1 20030313 US 2002-160972 20020531  
US 2003064984 A1 20030403 US 2002-161234 20020531  
US 2003073852 A1 20030417 US 2002-161233 20020531  
NZ 529788 A 20031219 NZ 2002-529788 20020531  
EP 1434778 A1 20040707 EP 2002-731994 20020531  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
JP 2005500273 T2 20050106 JP 2003-500089 20020531  
ZA 2003000735 A 20040623 ZA 2003-735 20030128  
PRIORITY APPLN. INFO.: US 2001-295196P P 20010531  
US 2001-295259P P 20010531  
US 2001-295342P P 20010531  
US 2001-304908P P 20010711  
WO 2002-US17210 W 20020531

OTHER SOURCE(S): MARPAT 138:4470

IT 477209-22-6P 477209-52-2P 477209-54-4P  
477209-56-6P 477209-59-9P 477209-60-2P  
477209-62-4P 477209-63-5P 477209-64-6P  
477209-66-6P 477209-64-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of duocarmycin analogs as potent cytotoxins)  
RN 477209-22-6 HCAPLUS  
CN L-Leucinamide, N-[[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[[2-[[[1,3-bis(4-chloromethyl)-5-cyano-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuran]amino]carbonyl]-5-benzofuran]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

LS ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2005 ACS ON STN


ACCESSION NUMBER: 2002:927432 HCAPLUS Full-text  
DOCUMENT NUMBER: 138:4470  
TITLE: Preparation of duocarmycin analogs as potent cytotoxins  
INVENTOR(S): Mg, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.

PATENT ASSIGNER(S): Coulter Pharmaceutical, Inc., USA  
SOURCE: PCT Int. Appl., 118 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| WO 2002096910  | A1   | 20021205 | WO 2002-US17210 | 20020531 |
| W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, |      |          |                 |          |

1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 477209-52-2 HCAPLUS

CN L-Leucinamide, N-[[[2-[[[2-[[[1S]-1-(chloromethyl)-5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477209-56-6 HCAPLUS




CN L-Leucinamide, N-[[[3-carboxy-1-oxopropyl]-β-alanyl-L-leucyl-L-alanyl-N-[[2-[[[2-[[[1S]-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477209-54-4 HCAPLUS



CN L-Leucinamide, N-[[[3-carboxy-1-oxopropyl]-β-alanyl-L-leucyl-L-alanyl-N-[[2-[[[2-[[[1S]-1-(chloromethyl)-5-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)




RN 477209-59-9 HCAPLUS

CN L-Leucinamide, N-[[[5-carboxy-1-oxopentyl]-β-alanyl-L-leucyl-L-alanyl-N-[[2-[[[2-[[[1S]-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[4-methyl-1-piperazinyl]carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 477209-62-4 HCAPLUS

CN L-Leucinamide, N-(1,6-dioxo-6-(phenylmethoxy)hexyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 477209-63-5 HCAPLUS

CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477209-64-6 HCAPLUS



CN L-Leucinamide, N-(5-carboxy-1-oxopentyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 477209-66-8 HCAPLUS

CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 477328-64-6 HCAPLUS

CN Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-leucylalanyl-N-[6-[[[2-[[[2-[[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]amino]-6-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:755199 HCAPLUS Full-text  
DOCUMENT NUMBER: 137:284323  
TITLE: Enzyme-cleavable prodrug compounds  
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.  
PATENT ASSIGNEE(S): Belg.  
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.  
DOCUMENT TYPE: CODEN: USXXCO  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 3 English  
PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| US 2002142955  | A1   | 20021003 | US 2001-879442  | 20010611 |
| WO 2000033888  | A2   | 20000615 | WO 1999-US30393 | 19991210 |
| WO 2000033888  | A3   | 20011108 |                 |          |
| W: AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, |      |          |                 |          |


hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-89-9 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG  
PRIORITY APPLN. INFO.: US 1998-111793P P 19981211  
US 1999-119312P P 19990208  
WO 1999-US30393 A2 19991210  
US 2000-211867P P 20000614  
US 2001-290448P P 20010511

OTHER SOURCE(S): MARPAT 137:284323  
IT 274912-87-7P 274912-88-8P 274912-89-9P  
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(thimet oligopeptidase-cleavable prodrug compds.)  
RN 274912-87-7 HCAPLUS  
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 274912-88-8 HCAPLUS  
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-

PAGE 1-B




IT 274912-95-7P 274912-96-8P 274913-03-0P  
274913-04-1P 274913-05-2P 274913-07-4P  
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(thimet oligopeptidase-cleavable prodrug compds.)  
RN 274912-95-7 HCAPLUS  
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS  
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 274913-03-0 HCAPLUS  
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-


propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucylamino]-α-L-lyxo-hexopyranosyloxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 274913-04-1 HCAPLUS

CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-05-2 HCAPLUS

CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Cecilia; Nieder, Matthew; Shochat, Dan; Yarranton, Geoffrey T.; Trouet, Andre  
CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg.  
SOURCE: Cancer Research (2002), 62(8), 2327-2331  
CODEN: CNREAS; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 274912-87-7


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity of CPI-0004Na)

RN 274912-87-7 HCAPLUS


CN 5,12-Naphthacenedione, 10-[[3-[[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucylamino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2005 ACS ON STN




RN 274913-07-4 HCAPLUS


CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucylamino]-α-L-lyxo-hexopyranosyloxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



LS ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2002:323079 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:241802

TITLE: CPI-0004Na, a new extracellularly tumor-activated

prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity  
Dubois, Vincent; Daenon, Luc; Lebahi, Karim; Collet, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai,

AUTHOR(S):

ACCESSION NUMBER: 2002:10314 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 136:86054

TITLE: Tripeptide prodrug compounds

Bebington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO.  | DATE       |
|------------------------|--|----------|------------------|------------|
| WO 2002000263          | A2   | 20020103 | WO 2001-US40925  | 20010611   |
| WO 2002000263          | A3   | 20020815 |                  |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |          |                  |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG   |          |                  |            |
| CA 2411545             | AA   | 20020103 | CA 2001-2411545  | 20010611   |
| EP 1294403             | A2   | 20030326 | EP 2001-942249   | 20010611   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR   |          |                  |            |
| JP 2004501875          | T2   | 20040122 | JP 2002-505044   | 20010611   |
| US 2003181359          | A1   | 20030925 | US 2002-311519   | 20021213   |
| PRIORITY APPLN. INFO.: |  |          | US 2000-212800 P | 20000614   |
|                        |  |          | WO 2001-US40925  | W 20010611 |

OTHER SOURCE(S): CASREACT 136:86054; MARPAT 136:86054

IT 274912-87-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(tripeptide prodrug compds.)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucylamino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyloxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






PAGE 1-B


DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2411660 AA 20011220 CA 2001-2411660 20010611  
 EP 1294405 A2 20030326 EP 2001-950291 20010611  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004510703 T2 20040408 JP 2002-510122 20010611  
 PRIORITY APPLN. INFO.: US 2000-211887P P 20000614  
 US 2001-290448P P 20010511  
 WO 2001-US18903 W 20010611

OTHER SOURCE(S): MARPAT 136:58787  
 IT 274912-87-7P 274912-88-8P 274912-89-9P  
 RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (enzyme-cleavable prodrug compds.)  
 RN 274912-87-7 HCAPLUS  
 CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-88-8 HCAPLUS  
 CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-


L5 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:923644 HCAPLUS Full-text  
 DOCUMENT NUMBER: 136:58787  
 TITLE: Enzyme-cleavable prodrug compounds  
 INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev;  
 Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre;  
 Varranton, Geoffrey T.  
 PATENT ASSIGNEE(S): Corixa Corporation, USA  
 SOURCE: PCT Int. Appl., 159 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2001095945 | A2   | 20011220 | WO 2001-US18903 | 20010611 |
| WO 2001095945 | A3   | 20020815 |                 |          |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-,  
 (8S,10S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-B


L5 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2001:653068 HCAPLUS Full-text  
 DOCUMENT NUMBER: 135:362468  
 TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity  
 AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Danois,  
 Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.;  
 Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.;  
 Shochat, Dan; Trouet, Andre  
 CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de  
 Louvain, Louvain-la-Neuve, B-1348, Belg.  
 SOURCE: Journal of Medicinal Chemistry (2001), 44(22),  
 3750-3753  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 372491-73-1P  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
 effector, except adverse); BSU (Biological study, unclassified); SPN  
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an  
 extracellularly tumor-activated prodrug devoid of i.v. acute toxicity)  
 RN 372491-73-1 HCAPLUS  
 CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, monosodium salt, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 1-B




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2000:401690 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 133:48878  
 TITLE: Oligopeptide prodrug compounds and process for preparation thereof  
 INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.  
 PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA  
 SOURCE: PCT Int. Appl., 125 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:


| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| WO 2000033888 | A2   | 20000615 | WO 1999-US30393 | 19991210 |
| WO 2000033888 | A3   | 20011108 |                 |          |

PAGE 1-B




RN 274912-88-8 HCAPLUS  
 CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 274912-89-9 HCAPLUS  
 CN 5,12-Naphthacenedione, 10-[[3-[[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2354766 AA 20000615 CA 1999-2354766 19991210  
 EP 1144011 A2 20011017 EP 1999-967462 19991210  
 EP 1144011 A3 20020206  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO  
 JP 2003518000 T2 20030603 JP 2000-586378 19991210  
 AU 773420 B2 20040527 AU 2000-23733 19991210  
 NZ 512171 A 20040730 NZ 1999-512171 19991210  
 US 2002142955 A1 20021003 US 2001-879442 20010611  
 PRIORITY APPLN. INFO.:  
 US 1998-111793P P 19981211  
 US 1999-119312P P 19990208  
 WO 1999-US30393 W 19991210  
 US 2000-211887P P 20000614  
 US 2001-290448P P 20010511


OTHER SOURCE(S): MARPAT 133:48878  
 IT 274912-87-7 274912-88-8 274912-89-9  
 274912-95-7 274912-96-8 274913-03-0  
 274913-04-1 274913-05-2 274913-07-4  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (oligopeptide prodrug compds. and process for preparation thereof)  
 RN 274912-87-7 HCAPLUS  
 CN 5,12-Naphthacenedione, 10-[[3-[[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 274912-95-7 HCAPLUS  
 CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS  
 CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 274913-03-0 HCAPLUS  
 CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[[2,3,6-trideoxy-3-[[[N-(4-methoxy-1,4-dioxo-4-(2-propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 274913-04-1 HCAPLUS  
 CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-B



RN 274913-05-2 HCAPLUS  
 CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274913-07-4 HCAPLUS  
 CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[[2,3,6-trideoxy-3-[[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



=> DIS HIST

(FILE 'HOME' ENTERED AT 07:28:10 ON 24 JUN 2005)

FILE 'REGISTRY' ENTERED AT 07:28:19 ON 24 JUN 2005  
 L1 STRUCTURE UPLOADED  
 L2 21 S L1 FUL  
 E DOXORUBICIN  
 L3 109 S E3  
 L4 0 L3 AND L2

FILE 'HCAPLUS' ENTERED AT 07:29:39 ON 24 JUN 2005  
 L5 13 S L2

FILE 'REGISTRY' ENTERED AT 07:30:13 ON 24 JUN 2005

FILE 'HCAPLUS' ENTERED AT 07:30:18 ON 24 JUN 2005

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 48.97            | 232.72        |

STN INTERNATIONAL LOGOFF AT 07:31:12 ON 24 JUN 2005